By visiting our website or using services provided by Sai Life Sciences, you are accepting the practices described in the Privacy Policy.

We also use cookies on our websites. Cookies allow us to give you the best browsing experience and help us to understand how you use our site. You can disable cookies but parts of our website may not work. By continuing to use this website, you agree that we may store and access cookies on your device.

By clicking “I Accept”, you confirm that you are above the age of 16, that you have read and understood the Cookies Usage and the Privacy Policy, and that you agree to the collection, use and processing of your Personal Information by Sai Life in accordance with said policies.

I accept

Stay up to date with our newsletter

Get in touch!

To explore career opportunities with Sai Life Sciences, share your CV here.

Lets start the conversation!

Sign up to our newsletter

Thank you!
We will be in touch shortly.

2025.04.03

Sai Life Sciences sets up Peptide Research Center in India

Sai Life Sciences Limited (BSE: 544306 I NSE: SAILIFE), an innovator focused Contract Research, Development, and Manufacturing Organization (CRDMO), has inaugurated a dedicated Peptide Research Center at its integrated R&D Campus in Hyderabad, India.


Announcing the launch, Krishna Kanumuri, CEO & Managing Director, Sai Life Sciences, said: “As the pharmaceutical industry evolves from small molecules to emerging modalities like peptides, we are expanding our capabilities to stay ahead. Our new Peptide Research Center reflects this commitment—designed to meet the growing demand for complex peptide synthesis and conjugation. With this investment, we reinforce our role as a trusted partner in advancing next-generation therapeutics.”

The Peptide Research Center is designed to support innovator pharma and biotech companies with specialized services across peptide synthesis, discovery, and advanced modalities, including complex conjugates. The facility integrates automation, advanced liquid handling, robotics, and high-throughput systems, enhancing precision, scalability, and efficiency in the development of novel peptide-based therapeutics.

Maneesh Pingle, Head of Discovery Services, said: “The demand for peptide-based therapeutics is rising rapidly, driven by their high specificity, biocompatibility, and lower risk of off-target effects. At Sai Life Sciences, we have a seasoned team of scientists with years of experience successfully delivering peptide discovery and development projects. Combined with our expanding capabilities, this expertise positions us strongly to support our clients’ evolving needs as they advance peptide therapies across diverse therapeutic areas."

The new Peptide Research Center will be integrated with Sai Life Sciences’ end-to-end discovery services, spanning synthetic and medicinal chemistry, biology, DMPK, and toxicology. This holistic approach ensures seamless transitions across different stages of drug discovery, accelerating timelines and enhancing success rates for peptide-based drug development.

By combining deep expertise, cutting-edge technology, and an integrated approach, Sai Life Sciences strengthens its commitment to supporting global clients in advancing innovative peptide therapeutics.

Share article

More News

2025.12.19

Sai Life Sciences Releases Sustainability Report 2025

Hyderabad, December 19, 2025: Sai Life Sciences Limited (BSE: 544306 | NSE: SAILIFE), one of India’s fastest-growing Contract Research, Development, and Manufacturing Organizations (CRDMO), today announced the release of its Sustainability Report for 2024–25. Aligned with the Global Reporting Initiative (GRI) Universal Standards 2021 and the Sustainability Accounting Standards Board (SASB) standards, this sixth edition […]
Read more

2025.12.15

Pushing Boundaries in Organic Chemistry: IISc Prof. Santanu Mukherjee at Sai Life Sciences

As part of Sai Life Sciences’ ongoing initiative to foster meaningful scientific engagement through interactions with distinguished researchers, Prof. Santanu Mukherjee, Professor in the Department of Organic Chemistry at IISc Bangalore, visited our Integrated R&D campus for a full-day programme of knowledge exchange. He delivered an insightful masterclass on his group’s work in enantioselective desymmetrization—a […]
Read more

2025.11.27

India is evolving from being a tactical supplier to a strategic partner to global pharma

Krishna Kanumuri, MD & CEO of Sai Life Sciences, was recently interviewed by Pharmaceutical Executive for its feature on next-generation CDMOs. In the interview, he shares insights on how Indian CDMOs are evolving from tactical suppliers to strategic partners, the shifting global supply-chain landscape, and how Sai Life Sciences is preparing for the opportunities and […]
Read more

2025.11.27

Decoding the Signals of Life: CDFD’s Dr. Rashna Bhandari visits Sai

Dr. Rashna Bhandari, Principal Investigator at the Centre for DNA Fingerprinting and Diagnostics (CDFD), Hyderabad, recently visited our Sai Life Sciences campus to deliver an insightful masterclass on “Phosphate-rich biomolecules in cell signalling.” In her session, Dr. Bhandari explored how phosphate-rich molecules act as vital messengers that regulate cellular communication and coordination. She explained how […]
Read more

2025.11.08

SLSC_Sankalp

Sai Life Sciences Launches Child Safety Awareness Program in Government Schools in Hyderabad with Sankalp

Raising awareness around child safety requires sensitivity and a collective effort to help children recognize unsafe situations and know how to respond. Guided by this purpose, Sai Life Sciences, in partnership with Sankalp NGO, has launched a Child Sexual Abuse Prevention Program across ten government schools in Gachibowli, Hyderabad. The program features two age-appropriate curriculums […]
Read more